IT’S that time of year again when we’re seemingly greeted with a new cough, sneeze or sniffle every week. But as we beat one ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Hosted on MSN5d
US FDA Approves First Of Its Kind Ketamine-Based Nasal Spray To Treat Depression: Know All About This DrugThe US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
Researchers delivered a dose of the “love hormone” oxytocin via a nasal spray to participants and found that it decreased ...
Hosted on MSN6d
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...
8d
On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII ...
Saline nasal drops also help flush out mucous and inflammatory mediators, which can improve cold symptoms and give the immune ...
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback